Open AccessPeer ReviewedPublished Monthly Since 2007 Vol. 19, Issue 12 · November 2026Media Kitinfo@guident.net

Conservative Treatment Options in Oral Submucous Fibrosis

  • Dr. Surej Kumar LKProfessor & HOD
  • Dr. Nikhil M KurienProfessor
  • Dr. Georgie P ZachariahJunior Resident

Department of Oral & Maxillofacial Surgery, PMS College of Dental Sciences and Research, Trivandrum

Guident · Volume 13, Issue 6 (May 2020)Published May 202010 min read

ABSTRACT

Oral submucous fibrosis (OSMF) is a potentially malignant disease or condition that results in progressive intraepithelial & juxta fibrosis of the oral soft tissues, and an eventual inability to open the mouth. The treatment of oral submucous fibrosis ranges from pharmacological means like iron, multivitamins including lycopene, spirulina, pentoxifylline, local submucosal injections of steroids, hyaluronidase and chylomicrons, an aqueous extract of healthy human placenta, and surgical excision of the fibrous tissues/bands.

INTRODUCTION

Oral Submucous Fibrosis, which is a relatively unknown disease in the early 60s, is now widely regarded as a precancerous condition.1 Oral submucous fibrosis (OSMF) is a potentially malignant disease that results in progressive juxta-epithelial fibrosis of the oral soft tissues, mainly occurring in the Indian subcontinent. It is a chronic, insidious, disabling disease involving oral mucosa, the oropharynx, and rarely, the larynx. OSMF results in an increasing loss of tissue mobility marked rigidity, and an eventual inability to open the mouth. 2,3 The most commonly involved site is buccal mucosa, followed by palate, retromolar region, faucial pillars, and pharynx.1 The etiopathogenesis of OSMF is complex and not fully understood. The principal agent involved in the etiopathogenesis of OSMF is areca nut. Areca nut is made up of alkaloid and flavonoid components. Four alkaloids, namely arecoline, arecaidine, guvacine, and guvacoline, have been identified in areca nut, of which arecoline is the most potent agent and plays a significant role in the pathogenesis of OSMF by causing an abnormal increase in collagen production.4 The compounds of tobacco products may act synergistically in the pathogenesis of oral mucosal lesions in areca quid chewers.4 Many treatment protocols for oral submucous fibrosis have been proposed to alleviate the signs and symptoms of the disorder. The patient is advised to quit the habit of betel nut chewing thoroughly. The treatment options of oral submucous fibrosis is rare, which includes iron, multivitamins including lycopene, pentoxifylline, local submucosal injections of steroids, chylomicrons and hyaluronidase, an aqueous extract of healthy human placenta, and surgical excision of the fibrous bands. OSF is adeptly recognized as a potentially malignant disorder.5,6

SURGICAL MANAGEMENT

In OSMF, there is atrophy of the mucosa and collagen deposition beneath the basement membrane. There is a decrease in ground substance, cellular elements, and vascularity with increasing fibrosis.7 Hence a deleterious effect on wound healing after dentoalveolar surgery is to be expected.
It is very unlikley that the patients will undertake extensive and scrupulous oral hygeine measures, because of pain, trismus, and mucosal irritation, thereby predisposing to wound infection.

DRUG TREATMENT

Corticosteroids

Corticosteroids are immunosuppressive agents that are believed to decrease inflammation and collagen formation, thereby reducing the symptoms and resulting in increased mouth opening. Corticosteroids such as hydrocortisone, triamcinolone, dexamethasone, and betamethasone have been used in the treatment of OSMF. Steroids suppress inflammatory reactions, thereby preventing fibrosis by decreasing fibroblastic proliferation and deposition of collagen.

A study by Borle RM et al.8 studied three hundred twenty-six patients with oral submucous fibrosis with conventional submucosal injections of steroids and hyaluronidase; and another group with a conventional therapy topical vitamin A, steroid applications, and oral iron preparations. The results were compared. The conventional treatment with injections was found to be hazardous, whereas the conservative treatment was found to be safe.
Another study by Ameer NT et al.9 evaluated the effect of intralesional triamcinolone in OSMF by giving biweekly submucosal injections of 40 mg triamcinolone for 12 weeks and followed up for a period of 1 year. The effect of therapy was evaluated subjectively by improvement in symptoms and objectively by an increase in mouth opening.

Enzymes

Enzymes such as collagenase, hyaluronidase, and chymotrypsin are being used for the treatment of OSMF. Hyaluronidase by breaking down hyaluronic acid (the ground substance in connective tissue) lowers the viscosity of inter¬cellular cement substance. Better results are observed concerning trismus and fibrosis. Patients receiving hyaluronidase alone showed a faster improvement in the burning sensation and painful ulceration produced by the effects of local by-products, although a combination of dexamethasone and hyaluronidase gave better long-term results than other regimens.10
Chymotrypsin hydrolyzes ester and peptide bonds and thus can be useful as a proteolytic and anti-inflammatory agent in the treatment of oral submucous fibrosis.11 Another enzyme of interest is collagenase, a lysosomal enzyme capable of degrading collagen. Intralesional injections of collagenases markedly improved mouth opening and at the same time, reduced the hypersensitivity to spices, sour-tasting foods, cold, and heat12.
In another study by Singh et al., no statistically significant difference in sign and symptom was seen in OSMF patients between hydrocortisone acetate and hyaluronidase versus triamcinolone acetonide and hyaluronidase13. The treatment regimen of group B was more convenient to the patients because less number of visits required and cheap. No side effects were evident. The authors concluded that hyaluronidase is much swifter in ameliorating painful ulceration and burning sensation than dexamethasone, but the effect is short term, although its combination with steroids gives somewhat better longer-term results.

Vitamins and minerals

Vitamins, micronutrients, and minerals are useful in controlling the burning sensation and ulceration in OSMF. In one study, OSMF patients received supplementation of vitamins and minerals for one to three years. Significant improvement in symptoms, like intolerance to spicy food, burning sensation, and mouth opening was observed at exit.14 Vitamins A, B, C, D, E, and minerals like copper, iron, and magnesium stabilize and deactivate the free radicals before they attack cells. In a study by Kumar A et al.15, oral lycopene therapy showed improvement in the signs and symptoms of OSMF. In a study by Shetty P et al.16, the efficacy of spirulina as an antioxidant adjuvant to corticosteroid injections in the management of 40 OSMF subjects of south Karnataka and north Kerala was evaluated. Syptomatic clinical improvements in mouth opening were significant in the posttreatment period in both Spirulina and placebo groups. The two groups showed a statistically significant reduction in a burning sensation. However, when both groups are compared, mouth opening and burning sensation was found to be statistically very highly significant in favor of the spirulina group. Spirulina can bring about symptomatic improvements in OSMF patients and can be put to use as adjuvant therapy in the inceptive management of OSMF patients.

Peripheral vasodilators

Vasodilators like pentoxifylline have vasodilating properties, and hampered mucosal vascularity in OSMF could be increased by the use of pentoxifylline. Pentoxifylline suppresses leucocyte function and alters fibroblast physiology and stimulates fibrinolysis. In one study, the effect of pentoxifylline was studied on the clinical and pathologic course of OSMF. This investigation was conducted as a randomized clinical trial incorporating a control group (Standard drug group SDG, multivitamin, and local heat therapy) in comparison to pentoxifylline test cases (Experimental drug group EDG, 400mg 3 times daily, as coated, sustained release tablets). The authors concluded that pentoxifylline could be used as an adjunct therapy in the management of oral submucous fibrosis.17 In another study, Pentoxifylline 400mg for a period of 7 months, showed an improvement in total signs and symptoms of OSMF. No significant side effects were observed.18 Oral isoxsuprine, as well as dexamethasone with hyaluronidase injections combined to physiotherapy, showed improvement in oral submucous fibrosis. Oral isoxsuprine may be a more effective treatment modality used in the management of OSMF.19

Other drugs

Drugs like interferon-gamma (IFN-gamma) is a known anti-fibrotic cytokine. In a study by Haque MF et al18 intralesional IFN-gamma treatment showed improvement in the patients mouth opening from an inter-incisal distance before treatment of 21 +/- 7 mm, to 30 +/- 7 mm immediately after treatment and 30 +/- 8 mm 6-months later, giving a net gain of 8 +/- 4 mm (42%) (range 4-15 mm). In this study, patients also reported reduced burning dysesthesia and increased the suppleness of the buccal mucosa.
Apart from the above therapies, immunized cow’s milk has shown promising results in OSMF.20 The milk from cows immunized with human intestinal bacteria contains an anti-in-flammatory component that suppresses the inflammatory reaction and modulates cytokine production in OSMF.

Ayurvedic therapy

Turmeric, as a spice and household remedy, has been known to be safe for centuries. Turmeric oil is proved to be effective in OSMF21 The anti-inflammatory, antioxidant, and antifibrotic properties of curcumin interfere with the progression of OSMF at multiple stages in the pathogenesis of this complex disease22 The antioxidative and scavenger properties of curcumin, making it a beneficial chemopreventive agent in the prevention of cancer. Tea, when used in combination with vitamins, with its antioxidant property, can bring about an improvement in mouth opening in OSMF.

CONCLUSION

Management of OSMF should include counseling of patients along with lycopene/spirulina/ multivitamin /minerals in the initial stages. Moderate stages of OSMF should be treated with intralesional steroids or pentoxifylline, whereas advanced stages may be treated surgically.

FUTURE RESEARCH OPPORTUNITIES

Epigenetic networks are increasingly considered to be essential elements in many human diseases and this is likely to include oral submucous fibrosis.23
Research on the role of epigenetic changes in the development of oral submucous fibrosis has just started to emerge. Epigenetic mechanisms have become significant contributors to our knowledge of the pathogenesis of many human diseases. As these alterations are frequent and reversible, they have become attractive candidates for the development of disease biomarkers and as targets of modern and emerging therapeutics in several human cancers. Given the understanding of epigenetics and combining the knowledge of genetic alterations, the focus of future research should be early diagnosis and the development of therapeutic strategies targeting epigenetic mechanisms.

REFERENCES

  1. Paissat DK. Oral submucous fibrosis. International Journal of Oral Surgery. 1981 Oct; 10(5): 307–12.
  2. Warnakulasuriya S, Johnson NewellW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa: Potentially malignant disorders. Journal of Oral Pathology & Medicine. 2007 Jul 26; 36(10): 575–80.
  3. Aziz SR. Oral submucous fibrosis: an unusual disease. J N J Dent Assoc. 1997; 68(2): 17–9.
  4. Chang Y-C, Hu C-C, Tseng T-H, Tai K-W, Lii C-K, Chou M-Y. Synergistic effects of nicotine on arecoline-induced cytotoxicity in human buccal mucosal fibroblasts. J Oral Pathol Med. 2001 Sep; 30(8): 458–64.
  5. Zain RBte, Ikeda N, Gupta PC, Warnakulasuriya S, Wyk CW, Shrestha P, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25-27, 1996. Journal of Oral Pathology & Medicine. 2007 Feb 27; 28 (1):1–4.
  6. Meghji S, Warnakulasuriya S. Oral submucous fibrosis: An expert symposium. Oral Diseases. 2008 Jun 28;3(4):276–276.
  7. Canniff JP, Harvey W, Harris M. Oral submucous fibrosis: its pathogenesis and management. Br Dent J. 1986 Jun; 160(12): 429–34.
  8. Borle RM, Borle SR. Management of oral submucous fibrosis: A conservative approach. Journal of Oral and Maxillofacial Surgery. 1991 Aug;49(8):788–91.
  9. Ameer NT, Shukla RK. A cross-sectional study of oral submucous fibrosis in central India and the effect of local triamcinolone therapy. Indian J Otolaryngol Head Neck Surg. 2012 Sep; 64(3): 240–3.
  10. Kakar PK, Puri RK, Venkatachalam VP. Oral Submucous Fibrosis—treatment with hyalase. J Laryngol Otol. 1985 Jan; 99(1): 57–60.
  11. Passi D, Bhanot P, Kacker D, Chahal D, Atri M, Panwar Y. Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies. Natl J Maxillofac Surg. 2017 Dec; 8(2): 89–94.
  12. Lin H-J, Lin J-C. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Diseases. 2007 Jul; 13(4): 407–13.
  13. Singh M, Niranjan HS, Mehrotra R, Sharma D, Gupta SC. Efficacy of hydrocortisone acetate/hyaluronidase vs. triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J Med Res. 2010 May; 131:665–9.
  14. Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementation in the management of oral submucous fibrosis in Karachi, Pakistan. Nutrition and Cancer. 1997 Jan; 27(1):41–7.
  15. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2007 Feb; 103(2):207–13.
  16. Shetty P, Shenai P, Chatra L, Rao P. Efficacy of spirulina as an antioxidant adjuvant to corticosteroid injection in the management of oral submucous fibrosis. Indian J Dent Res. 2013; 24(3):347.
  17. Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy : A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res. 2006; 17(4):190.
  18. Mehrotra R, Singh HP, Gupta SC, Singh M, Jain S. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian Pac J Cancer Prev 2011; 12(4):971–4.
  19. Bhadage CJ, Umarji HR, Shah K, Välimaa H. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis. Clin Oral Invest.
  20. 2013 Jun; 17(5):1375–82.
  21. Haque MF, Meghji S, Nazir R, Harris M. Interferon-gamma (IFN-gamma) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001 Jan; 30(1):12–21.
  22. Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements in symptoms and signs in patients with oral submucous fibrosis. J Oral Pathol Med. 2001 Nov; 30(10):618–25.
  23. Joshi J, Ghaisas S, Vaidya A, Vaidya R, Kamat DV, Bhagwat AN, et al. Early human safety study of turmeric oil (Curcuma longa oil) administered orally in healthy volunteers. J Assoc Physicians India. 2003 Nov; 51:1055–60.
  24. Xu C, Zhao J, Loo WTY, Hao L, Wang M, Cheung MNB, et al. Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis. JBM. 2012; 27(4):314–21.

Disclaimer from Guident

The views and opinions expressed in articles published in Guident are solely those of the authors and do not necessarily reflect the views of the editors, the editorial board or the publisher, Ivory India. Guident does not endorse any product, technique or treatment described. Clinical content is intended for qualified dental and medical professionals and is not a substitute for individual clinical judgement. Guident, its editors and the publisher accept no liability for any consequence arising from the use of information published in the journal.

How to cite this article

Dr. Surej Kumar LK, Dr. Nikhil M Kurien, Dr. Georgie P Zachariah. Conservative Treatment Options in Oral Submucous Fibrosis. Guident. 2020 May;13(6). Available from: https://ivoryindia.in/articles/oral-surgery/conservative-treatment-options-in-oral-submucous-fibrosis.html

Related articles

More in Oral Surgery

All 60 articles
Vol. 13, Issue 7 · June 2020

Traumatic Induced Mucocele of the Lower Lip

Oral mucocele is an very common entity of the minor salivary gland usually caused due to trauma or obstruction of the minor salivary gland. They are classified either as retention or…

Dr. Omkar Shetye

Vol. 13, Issue 4 · March 2020

Facial Rejuvenation the Resurgence

Confidence always breeds beauty. Aging is a natural phenomenon that we cannot resist. But the demand for the youthful look is always on high demand. Here comes the remarkable achievement in…

Dr. Nikhil M Kurien

Call for papers

Publish your clinical work in Guident

Original research, case reports and review articles are welcomed from clinicians and researchers worldwide. Every submission is assessed by the editorial board.